A Phase 1B Multicenter,Open-labelStudy to determine the recommended dose and Regimen of Durvalumab(MEDI4736)ceither as Monotherapy or in combination with Pomalidomide(Pom) with or without Low-dose Dexamethasone(Dex) in subjects with relapsed and refractory Multiple Myeloma(RRMM).